The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.

Abstract

The objective of this study is to investigate how the change of hormone receptor (HR) and human epidermal growth factor receptor-2 (Her-2) status is related to patients' clinical features. One hundred ninety-three cases of patients treated at general hospital of PLA from 2000 to 2015 with advanced breast cancer were included. All patients developed recurrence that were re-biopsied and had complete pathological profile both at initial diagnosis and at relapse. HR status before and after relapse were available for all patients, while only 143 cases had Her-2 status at the two stages. The changes of ER, PR, and Her-2 status and their association with clincopathological factors and DFS were analyzed. The discordant rates of ER, PR, and Her-2 status between primary breast cancer and recurrent tumor were 34.2, 38.3, and 16.8%, respectively. At relapse, the rates of gain of ER and PR positivity were 10.9 and 13.5%, respectively; the rates of loss of ER and PR positivity were 23.3 and 24.9%. Loss of positivity was more frequent than gain of positivity (p ER < 0.000, p PR = 0.001). Among patients with Her-2 negative primary tumors, 15.4% acquired Her-2 positivity at relapse; and among Her-2 positive patients at initial diagnosis, 1.4% turned to Her-2 negative at relapse; gain of positivity was more frequent than loss of positivity (p < 0.000). Patients with tumor larger than 2cm in diameter were more likely to experience change of Her-2 status (25.0 vs 5.8%, p = 0.005). Yet, the change of ER/PR was not significantly associated with the size of primary tumor. Patients with ER positive recurrent disease and PR positive primary tumor had a DFS of more than 40months. Compared to patients who maintained PR negative, patients who gained PR positivity at relapse had significantly longer DFS by 8.5% (35.2 vs 26.7months, p = 0.024). Patients losing ER positivity at relapse had shorter DFS by 7.8months compared to those with stable ER positive tumors; patients gaining ER positivity experienced longer DFS by 8.3months; but both differences were not statistically significant. Loss of Her-2 positivity was associated with longer DFS by 13.8months as opposed to stable Her-2 status, without statistical significance. For patients with Her-2 negative primary tumor, the changes of Her-2 status were not associated with DFS. 34.2, 38.3, and 16.8% of breast cancer patients had their ER, PR, and Her-2 status changed after recurrence, and these changes of receptor status were associated with DFS to some degree. Gain of PR positivity at relapse was significantly correlated with longer DFS.